Daclatasvir
- Generic Name
- Daclatasvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C40H50N8O6
- CAS Number
- 1009119-64-5
- Unique Ingredient Identifier
- LI2427F9CI
- Background
Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a si...
- Indication
Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 2
- Associated Therapies
- -
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)
- Conditions
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT01017575
- Locations
- 🇯🇵
Local Institution, Musashino-Shi, Tokyo, Japan
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 51
- Registration Number
- NCT01016912
- Locations
- 🇯🇵
Local Institution, Minato-Ku, Tokyo, Japan
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 215
- Registration Number
- NCT01012895
- Locations
- 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Carolinas Center For Liver Disease, Statesville, North Carolina, United States
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT00983957
- Locations
- 🇺🇸
MDS Pharma Services (US), Inc, Tempe, Arizona, United States
🇺🇸Covance Clinical Research Unit, Inc., Austin, Texas, United States
🇨🇦Local Institution, St. Laurent, Quebec, Canada
Drug-Drug Interaction Study in Healthy Subjects
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT00904059
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
- Conditions
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT00874770
- Locations
- 🇺🇸
Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸Llc Dba The Research Institute, Springfield, Massachusetts, United States
🇺🇸Veterans Affairs Medical Center, Bronx, New York, United States
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00859053
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 167
- Registration Number
- NCT00663208
- Locations
- 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇵🇷Local Institution, Santurce, Puerto Rico
🇺🇸Advanced Clinical Res Inst, Anaheim, California, United States
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 95
- Registration Number
- NCT00546715
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸University Of Virginia Digestive Health Center Of Excellence, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.